Associated Papers
Comprehensive characterization of PTEN mutational profile in a series of 34,129 colorectal cancers.
Serebriiskii IG et al.
Nature Communications, 2022
35338148 (PubMed )
Supplement: 41467_2022_29227_MOESM6_ESM.xlsx › Supplemenraty_Data_3
Comprehensive molecular profiling of Taiwanese breast cancers revealed potential therapeutic targets: prevalence of actionable mutations among 380 targeted sequencing analyses.
Huang CC et al.
Bmc Cancer, 2021
Whole-genome sequencing of glioblastoma reveals enrichment of non-coding constraint mutations in known and novel genes.
Sakthikumar S et al.
Genome Biology, 2020
32513296 (PubMed )
Supplement: 13059_2020_2035_MOESM3_ESM.xlsx › Additional_file_3_-_Table_S2
Immune dysregulation in patients with PTEN hamartoma tumor syndrome: Analysis of FOXP3 regulatory T cells.
Chen HH et al.
The Journal of Allergy and Clinical Immunology, 2017
Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors.
Mendes-Pereira AM et al.
Embo Molecular Medicine, 2009
20049735 (PubMed )
Supplement: emmm0001-0315-SD1.pdf
Select a paper to view details